Neoadjuvant chemoradiation compared to neoadjuvant radiation alone and surgery alone for Stage II and III soft tissue sarcoma of the extremities

Kelly K. Curtis, Jonathan B. Ashman, Christopher P. Beauchamp, Adam J. Schwartz, Matthew D. Callister, Amylou Dueck, Leonard L. Gunderson, Tom R. Fitch

Research output: Contribution to journalArticle

20 Citations (Scopus)

Abstract

Background: Neoadjuvant chemoradiation (NCR) prior to resection of extremity soft tissue sarcoma (STS) has been studied, but data are limited. We present outcomes with NCR using a variety of chemotherapy regimens compared to neoadjuvant radiation without chemotherapy (NR) and surgery alone (SA).Methods: We conducted a retrospective chart review of 112 cases.Results: Treatments included SA (36 patients), NCR (39 patients), and NR (37 patients). NCR did not improve the rate of margin-negative resections over SA or NR. Loco-regional relapse-free survival, distant metastases-free survival, and overall survival (OS) were not different among the treatment groups. Patients with relapsed disease (OR 11.6; p = 0.01), and tumor size greater than 5 cm (OR 9.4; p = 0.01) were more likely to have a loco-regional recurrence on logistic regression analysis. Significantly increased OS was found among NCR-treated patients with tumors greater than 5 cm compared to SA (3 year OS 69 vs. 40%; p = 0.03). Wound complication rates were higher after NCR compared to SA (50 vs. 11%; p = 0.003) but not compared to NR (p = 0.36). Wet desquamation was the most common adverse event of NCR.Conclusions: NCR and NR are acceptable strategies for patients with STS. NCR is well-tolerated, but not clearly superior to NR.

Original languageEnglish (US)
Article number91
JournalRadiation Oncology
Volume6
Issue number1
DOIs
StatePublished - Aug 9 2011

Fingerprint

Sarcoma
Extremities
Radiation
Survival
Recurrence
Drug Therapy
Neoplasms
Logistic Models
Regression Analysis
Neoplasm Metastasis
Wounds and Injuries
Therapeutics

Keywords

  • Chemoradiation
  • Chemotherapy
  • Extremity
  • Neoadjuvant
  • Radiation
  • Soft tissue sarcoma

ASJC Scopus subject areas

  • Oncology
  • Radiology Nuclear Medicine and imaging
  • Medicine(all)

Cite this

Neoadjuvant chemoradiation compared to neoadjuvant radiation alone and surgery alone for Stage II and III soft tissue sarcoma of the extremities. / Curtis, Kelly K.; Ashman, Jonathan B.; Beauchamp, Christopher P.; Schwartz, Adam J.; Callister, Matthew D.; Dueck, Amylou; Gunderson, Leonard L.; Fitch, Tom R.

In: Radiation Oncology, Vol. 6, No. 1, 91, 09.08.2011.

Research output: Contribution to journalArticle

Curtis, Kelly K. ; Ashman, Jonathan B. ; Beauchamp, Christopher P. ; Schwartz, Adam J. ; Callister, Matthew D. ; Dueck, Amylou ; Gunderson, Leonard L. ; Fitch, Tom R. / Neoadjuvant chemoradiation compared to neoadjuvant radiation alone and surgery alone for Stage II and III soft tissue sarcoma of the extremities. In: Radiation Oncology. 2011 ; Vol. 6, No. 1.
@article{736205e4d8f348adbf1a09ee92c306cd,
title = "Neoadjuvant chemoradiation compared to neoadjuvant radiation alone and surgery alone for Stage II and III soft tissue sarcoma of the extremities",
abstract = "Background: Neoadjuvant chemoradiation (NCR) prior to resection of extremity soft tissue sarcoma (STS) has been studied, but data are limited. We present outcomes with NCR using a variety of chemotherapy regimens compared to neoadjuvant radiation without chemotherapy (NR) and surgery alone (SA).Methods: We conducted a retrospective chart review of 112 cases.Results: Treatments included SA (36 patients), NCR (39 patients), and NR (37 patients). NCR did not improve the rate of margin-negative resections over SA or NR. Loco-regional relapse-free survival, distant metastases-free survival, and overall survival (OS) were not different among the treatment groups. Patients with relapsed disease (OR 11.6; p = 0.01), and tumor size greater than 5 cm (OR 9.4; p = 0.01) were more likely to have a loco-regional recurrence on logistic regression analysis. Significantly increased OS was found among NCR-treated patients with tumors greater than 5 cm compared to SA (3 year OS 69 vs. 40{\%}; p = 0.03). Wound complication rates were higher after NCR compared to SA (50 vs. 11{\%}; p = 0.003) but not compared to NR (p = 0.36). Wet desquamation was the most common adverse event of NCR.Conclusions: NCR and NR are acceptable strategies for patients with STS. NCR is well-tolerated, but not clearly superior to NR.",
keywords = "Chemoradiation, Chemotherapy, Extremity, Neoadjuvant, Radiation, Soft tissue sarcoma",
author = "Curtis, {Kelly K.} and Ashman, {Jonathan B.} and Beauchamp, {Christopher P.} and Schwartz, {Adam J.} and Callister, {Matthew D.} and Amylou Dueck and Gunderson, {Leonard L.} and Fitch, {Tom R.}",
year = "2011",
month = "8",
day = "9",
doi = "10.1186/1748-717X-6-91",
language = "English (US)",
volume = "6",
journal = "Radiation Oncology",
issn = "1748-717X",
publisher = "BioMed Central",
number = "1",

}

TY - JOUR

T1 - Neoadjuvant chemoradiation compared to neoadjuvant radiation alone and surgery alone for Stage II and III soft tissue sarcoma of the extremities

AU - Curtis, Kelly K.

AU - Ashman, Jonathan B.

AU - Beauchamp, Christopher P.

AU - Schwartz, Adam J.

AU - Callister, Matthew D.

AU - Dueck, Amylou

AU - Gunderson, Leonard L.

AU - Fitch, Tom R.

PY - 2011/8/9

Y1 - 2011/8/9

N2 - Background: Neoadjuvant chemoradiation (NCR) prior to resection of extremity soft tissue sarcoma (STS) has been studied, but data are limited. We present outcomes with NCR using a variety of chemotherapy regimens compared to neoadjuvant radiation without chemotherapy (NR) and surgery alone (SA).Methods: We conducted a retrospective chart review of 112 cases.Results: Treatments included SA (36 patients), NCR (39 patients), and NR (37 patients). NCR did not improve the rate of margin-negative resections over SA or NR. Loco-regional relapse-free survival, distant metastases-free survival, and overall survival (OS) were not different among the treatment groups. Patients with relapsed disease (OR 11.6; p = 0.01), and tumor size greater than 5 cm (OR 9.4; p = 0.01) were more likely to have a loco-regional recurrence on logistic regression analysis. Significantly increased OS was found among NCR-treated patients with tumors greater than 5 cm compared to SA (3 year OS 69 vs. 40%; p = 0.03). Wound complication rates were higher after NCR compared to SA (50 vs. 11%; p = 0.003) but not compared to NR (p = 0.36). Wet desquamation was the most common adverse event of NCR.Conclusions: NCR and NR are acceptable strategies for patients with STS. NCR is well-tolerated, but not clearly superior to NR.

AB - Background: Neoadjuvant chemoradiation (NCR) prior to resection of extremity soft tissue sarcoma (STS) has been studied, but data are limited. We present outcomes with NCR using a variety of chemotherapy regimens compared to neoadjuvant radiation without chemotherapy (NR) and surgery alone (SA).Methods: We conducted a retrospective chart review of 112 cases.Results: Treatments included SA (36 patients), NCR (39 patients), and NR (37 patients). NCR did not improve the rate of margin-negative resections over SA or NR. Loco-regional relapse-free survival, distant metastases-free survival, and overall survival (OS) were not different among the treatment groups. Patients with relapsed disease (OR 11.6; p = 0.01), and tumor size greater than 5 cm (OR 9.4; p = 0.01) were more likely to have a loco-regional recurrence on logistic regression analysis. Significantly increased OS was found among NCR-treated patients with tumors greater than 5 cm compared to SA (3 year OS 69 vs. 40%; p = 0.03). Wound complication rates were higher after NCR compared to SA (50 vs. 11%; p = 0.003) but not compared to NR (p = 0.36). Wet desquamation was the most common adverse event of NCR.Conclusions: NCR and NR are acceptable strategies for patients with STS. NCR is well-tolerated, but not clearly superior to NR.

KW - Chemoradiation

KW - Chemotherapy

KW - Extremity

KW - Neoadjuvant

KW - Radiation

KW - Soft tissue sarcoma

UR - http://www.scopus.com/inward/record.url?scp=79961153219&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79961153219&partnerID=8YFLogxK

U2 - 10.1186/1748-717X-6-91

DO - 10.1186/1748-717X-6-91

M3 - Article

C2 - 21827676

AN - SCOPUS:79961153219

VL - 6

JO - Radiation Oncology

JF - Radiation Oncology

SN - 1748-717X

IS - 1

M1 - 91

ER -